Misc - SASAKI Yasushi

胃底線ポリポーシスを背景とした胃腺窩上皮癌

足立 靖, 見田 裕章, 岩田 徳和, 佐々木 泰史, 安達 靖代, 吉田 幸成, 遠藤 高夫, 石井 良文, 後藤 啓

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  62回   P29 - 6  2024.10

内視鏡的切除により診断できた皮膚様食道扁平上皮癌

足立 靖, 菊地 剛史, 後藤 啓, 吉田 幸成, 石井 良文, 高橋 宏明, 佐々木 泰史, 仲瀬 裕志, 遠藤 高夫

日本消化管学会雑誌 ( (一社)日本消化管学会 )  8 ( Suppl. ) 360 - 360  2024.01

Liver metastasis recurrence of gastric adenocarcinoma mixed with neuroendocrine cancer

足立靖, 足立靖, 見田裕章, 佐々木泰史, 吉田幸成, 遠藤高夫, 石井良文, 西田靖仙, 奥田博介, 高橋宏明, 後藤啓

日本がん転移学会学術集会・総会プログラム抄録集   33rd  2024

J-GLOBAL

RAS野生型進行大腸癌に対する抗EGFR抗体治療におけるDroplet Digital PCRを用いた血中循環腫瘍DNAのモニタリング前向き観察研究

高橋直樹, 中村慶史, 木藤陽介, 久保田英嗣, 朝山雅子, 粂川陽祐, 原浩樹, 松島知広, 辻国広, 片岡洋望, 津矢田明泰, 佐々木泰史, 井戸川雅史, 時野隆至, 澤田武

大腸癌研究会プログラム・抄録集   101st  2024

J-GLOBAL

症例報告からPrecision Medicineへ-第1部- 悪性貧血を伴う自己免疫性胃炎における胃癌と食道癌の同時発生(Simultaneous cancers of the stomach and esophagus in autoimmune gastritis with pernicious anemia)

足立 靖, 久保 俊之, 佐々木 泰史, 安達 靖代, 吉田 幸成, 遠藤 高夫, 石井 良文, 高橋 宏明, 後藤 啓

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  61回   ICCJ1 - 3  2023.10

Association of serum superoxide dismutase activity and the incidence of colorectal cancer in a nested case-control study.

Yasushi Adachi, Masanori Nojima, Mitsuru Mori, Hiro-O Yamano, Yasushi Sasaki, Hiroshi Nakase, Yingsong Lin, Kenji Wakai, Akiko Tamakoshi

Cancer epidemiology ( (一社)日本癌学会 )  87   102455 - 102455  2023.09  [International journal]

　View Summary

BACKGROUND: Superoxide dismutase (SOD) is an antioxidant enzyme that degrades superoxide, a major causative factor in carcinogenesis. We assessed associations between serum SOD activities and incidence of colorectal carcinoma (CRC) in a case-control study nested in the Japan Collaborative Cohort (JACC) study. METHODS: At baseline, 39,242 subjects donated serum samples. Participants diagnosed with CRC during follow-up were regarded as cases. Odds ratios (ORs) for CRC incidence associated with SOD were evaluated with conditional logistic regression models. In the current study, 176 cases and 524 controls were analyzed. RESULTS: For the overall cohort, a decreasing trend in risk of CRC with increasing SOD was observed (P for trend=0.054) and the fourth quartile of SOD level showed the lowest risk compared to the first (OR=0.52, 95% confidence interval [CI]=0.29-0.93). This was significant in men (P for trend=0.001), with the fourth quartile of SOD level showing the lowest risk compared to the first (OR, 0.23; 95%CI, 0.09-0.60). It was also exclusively observed for rectal cancer and left-sided CRC (P for trend, 0.037 and 0.020, respectively), with the fourth quartile again showing the lowest risk compared to the first (OR, 0.28 and 0.38; 95%CI, 0.09-0.84 and 0.16-0.91, respectively). Limiting subjects to those followed-up over 2 years, all trends remained unchanged. CONCLUSIONS: Our findings suggest that serum SOD activity correlates inversely with risk of CRC, particularly in men and individuals with rectal cancer/left-sided CRC.

DOI PubMed

血清可溶性Fas値と肝臓癌罹患リスク(Serum soluble Fas levels and incidence of liver cancer)

足立 靖, 野島 正寛, 森 満, 久保 俊之, 阿久津 典之, 佐々木 泰史, 仲瀬 裕志, 遠藤 高夫, 林 櫻松, 若井 建志, 玉腰 暁子

日本癌学会総会記事 ( (一社)日本癌学会 )  82回   125 - 125  2023.09

Prospective observational study of monitoring gene alterations in plasma cell-free DNA using droplet digital PCR system during anti-EGFR antibody treatment in patients with RAS wild-type advanced colorectal cancer.

Naoki Takahashi, Keishi Nakamura, Yosuke Kito, Eiji Kubota, Masako Asayama, Yosuke Kumekawa, Hiroki Hara, Tomohiro Matsushima, Kunihiro Tsuji, Hiromi Kataoka, Akihiro Tsuyada, Yasushi Sasaki, Masashi Idogawa, Takashi Tokino, Takeshi Sawada

Journal of Clinical Oncology ( American Society of Clinical Oncology (ASCO) )  41 ( 4_suppl ) 172 - 172  2023.02

Research paper, summary (international conference)  

　View Summary

172 Background: Anti-EGFR antibody is recommended as one of the standard treatments in patients with RAS wild-type advanced colorectal cancer (CRC). Few reports have evaluated low-frequency subclones of alterations in EGFR signaling pathway genes in plasma cell-free DNA (cfDNA) during anti-EGFR treatment in prospective cohort of advanced CRC patients. Methods: Key inclusion criteria of this study was as follows: 20 years old and over, performance status 0 to 2, metastatic or recurrent CRC (adenocarcinoma), RAS wild-type CRC diagnosed by PCR-rSSO using tumor tissue, no prior use of anti-EGFR antibody. Plasma samples were prospectively collected at pre-treatment, at 4, 10 weeks, every 10 weeks thereafter, and at the end of the anti-EGFR treatment. With QX200 Droplet Digital PCR platform, we analyzed hotspot mutations of KRAS, NRAS, BRAF, and PIK3CA and copy number (CN) variant of HER2 and MET using plasma samples of pre- and post-treatment as well as during treatment (limited to patients with any gene alterations at pre- and post-treatment). Results: Total 50 patients were registered in this study, but 3 patients were excluded because inclusion criteria were not met. Finally, 47 patients were included in full analysis set. In 15 patients (31.9%), genetic alterations including KRAS (G12G13: 10.1%, A59Q61: 2.2%), NRAS (G12G13: 2.2%, Q61: 2.1%), BRAF (V600: 6.4%) , PIK3CA (E545: 4.3%, H1047: 4.3%) , and HER2 (amplification: 6.5%) were detected in pre-treatment samples. Analysis of pre-treatment samples showed that response rates of patients with any gene alterations (N = 13) and that without any gene alterations (N = 29) were 30.8% and 58.6%, respectively (p = 0.095). When the cut-off of variant allele frequency (VAF) was set as 0.5% in patients with any gene mutations, the response rates for cases with VAF ≥0.5% (N = 6) and those with VAF < 0.5% (N = 7) were 0% and 57.1%, respectively (p = 0.049). Among 41 patients with detectable target lesions by CT scan, there was significant difference in percentage of best tumor shrinkage between patients with gene alterations and those without gene alterations (32.1% vs 10.5%, p = 0.037), when cut-off VAF of any gene mutations was set as 0.5% and cut-off CN of HER2 or MET was set as 4 at pre-treatment. Due to dynamics of each gene alteration in cfDNA during treatment, mutations of KRAS A59Q61, NRAS Q61, and MET amplification were characterized as acquired alterations which were newly detected after the administration of anti-EGFR antibodies. Conclusions: Our study demonstrated the clinical relevance of minor mutant subclones in EGFR signaling pathway genes in plasma for predicting response to anti-EGFR treatment. Although sample size of this study was small, preferable threshold for distinguishing responders from non-responders may be 0.5% as VAF of these gene mutations. Clinical trial information: 000034923 .

DOI

非乳頭部十二指腸腫瘍におけるERBB受容体ファミリーの解析と治療標的の探索

佐々木泰史, 澤田武, 中村慶史

金沢大学がん進展制御研究所がんの転移・薬剤耐性に関わる先導的共同研究拠点   2022  2023

J-GLOBAL

Simultaneous cancers of the stomach and esophagus in autoimmune gastritis with pernicious anemia

足立靖, 足立靖, 久保俊之, 久保俊之, 佐々木泰史, 安達靖代, 吉田幸成, 遠藤高夫, 石井良文, 高橋宏明, 後藤啓

日本癌治療学会学術集会(Web) ( (一社)日本癌治療学会 )  61st   ICCJ1 - 3  2023

J-GLOBAL

Molecular mechanisms of suppression of Claudin-1 expression in oral cancer cell lines

丹下正一朗, 井戸川雅史, 川島秀器, 佐々木泰史, 時野隆至

日本分子生物学会年会プログラム・要旨集(Web)   46th  2023

J-GLOBAL

FGF受容体ファミリーの変異が子宮頸癌放射線治療予後に及ぼす影響

吉本由哉, 佐々木泰史, 尾池貴洋, 安藤謙, 濱本純子, 鈴木義行, 中野隆史, 時野隆至, 大野達也

日本免疫治療学会学術集会プログラム・抄録集   20th  2023

J-GLOBAL

血清SOD活性と大腸癌罹患リスク(Association of serum superoxide dismutase activity and the incidence of colorectal cancer in a nested case-control study)

足立 靖, 野島 正寛, 森 満, 久保 俊之, 山野 泰穂, 佐々木 泰史, 仲瀬 裕志, 遠藤 高夫, 林 櫻松, 若井 建志, 玉腰 暁子

日本癌学会総会記事 ( (一社)日本癌学会 )  81回   E - 3034  2022.09

Molecular profiling of cancer-related gene alterations in Japanese patients with multiple myeloma.

Sasaki Y, Fukushima H, Ikeda H, Ishiguro K, Matsuda M, Tange S, Idogawa M, Sakurai A, Tokino T

40th Sapporo International Cancer Symposium    2022.06

Authorship：   Lead author

Research paper, summary (international conference)  

Superoxide dismutase (SOD) activity and the risk of esophageal cancer in a nested case-control study

足立靖, 野島正寛, 森満, 久保俊之, 久保俊之, 佐々木泰史, 仲瀬裕志, 遠藤高夫, 林櫻松, 若井建志, 玉腰暁子

日本消化器癌発生学会総会プログラム・抄録集   33rd  2022

Research paper, summary (national, other academic conference)  

J-GLOBAL

非乳頭部十二指腸腫瘍におけるERBB受容体ファミリーの解析と治療標的の探索

佐々木泰史, 澤田武, 太田亮介

金沢大学がん進展制御研究所がんの転移・薬剤耐性に関わる先導的共同研究拠点   2021  2022

J-GLOBAL

Superoxide dismutase (SOD) activity and the risk of esophageal cancer in a nested case-control study

足立靖, 足立靖, 野島正寛, 森満, 久保俊之, 久保俊之, 佐々木泰史, 仲瀬裕志, 遠藤高夫, 林櫻松, 若井建志, 玉腰暁子

日本消化器癌発生学会総会プログラム・抄録集   33rd  2022

J-GLOBAL

FGF受容体ファミリーの変異が子宮頸癌放射線治療予後に及ぼす影響

吉本由哉, 吉本由哉, 佐々木泰史, 尾池貴洋, 安藤謙, 濱本純子, 鈴木義行, 中野隆史, 時野隆至, 大野達也

日本バイオセラピィ学会学術集会総会プログラム・抄録集   35th  2022

J-GLOBAL

症例特異的変異を用いた頭頸部扁平上皮癌におけるctDNAモニタリング

古後 龍之介, 真子 知美, 岩谷 岳, 西塚 哲, 佐々木 泰史, 井戸川 雅史, 時野 隆至, 中川 尚志

日本癌学会総会記事 ( (一社)日本癌学会 )  80回   [J14 - 6]  2021.09

RAS野生型転移性大腸癌患者における循環腫瘍DNA中のRAS、BRAF、PIK3CA変異の同定と腫瘍組織の変異との比較

澤田 武, 久保田 英嗣, 中村 慶史, 高橋 直樹, 太田 亮介, 井戸川 雅史, 佐々木 泰史, 時野 隆至, 源 利成, 片岡 洋望

日本癌学会総会記事 ( (一社)日本癌学会 )  80回   [P15 - 6]  2021.09